Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADILNASDAQ:ADXSNASDAQ:ALRNNASDAQ:ONCSNASDAQ:TLGT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$2.17-6.5%$1.61$0.76▼$14.00$8.79M1.485.35 million shs153,407 shsADXSAyala Pharmaceuticals$0.57-12.3%$0.72$0.50▼$1.95$6.13M1.6221,878 shs9,468 shsALRNAileron Therapeutics$5.00+17.6%$5.40$1.01▼$7.42$24.45M2.2263,107 shs1.75 million shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsTLGTTeligent$0.03$0.17▼$1.60N/AN/AN/A6,460 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals+3.57%-0.43%+42.33%+78.28%-69.79%ADXSAyala Pharmaceuticals+7.40%+5.82%+8.05%+7.48%-47.94%ALRNAileron Therapeutics-20.56%-26.85%-21.44%+0.47%+159.15%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-73.09%TLGTTeligent0.00%0.00%0.00%0.00%0.00%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AALRNAileron Therapeutics1.9682 of 5 stars3.53.00.00.02.91.70.0ONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial PharmaceuticalsN/AN/AN/AN/AADXSAyala Pharmaceuticals2.00HoldN/AN/AALRNAileron Therapeutics3.00Buy$19.00280.00% UpsideONCSOncoSec MedicalN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/ACurrent Analyst RatingsLatest TLGT, ONCS, ALRN, ADIL, and ADXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$2.46 per shareN/AADXSAyala Pharmaceuticals$10K612.75N/AN/A($0.61) per share-0.93ALRNAileron TherapeuticsN/AN/AN/AN/A$4.10 per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/ATLGTTeligentN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$5.12M-$5.72N/AN/AN/AN/A-250.52%-183.24%5/10/2024 (Estimated)ADXSAyala PharmaceuticalsN/A-$7.98N/A∞N/AN/A-2,798.92%-195.41%5/21/2024 (Estimated)ALRNAileron Therapeutics-$27.33M-$3.38N/A∞N/AN/A-83.80%-72.25%5/13/2024 (Estimated)ONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/ATLGTTeligentN/AN/A0.00N/AN/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AALRNAileron TherapeuticsN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A4.904.90ADXSAyala PharmaceuticalsN/A0.530.53ALRNAileron TherapeuticsN/A7.887.88ONCSOncoSec MedicalN/A0.890.89TLGTTeligentN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%ADXSAyala Pharmaceuticals7.18%ALRNAileron Therapeutics90.89%ONCSOncoSec Medical8.69%TLGTTeligentN/AInsider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals14.47%ADXSAyala Pharmaceuticals0.63%ALRNAileron Therapeutics5.57%ONCSOncoSec Medical1.32%TLGTTeligent0.17%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals164.05 million3.47 millionNo DataADXSAyala PharmaceuticalsN/A10.75 million10.68 millionNot OptionableALRNAileron Therapeutics64.89 million4.61 millionNot OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionableTLGTTeligent2,357N/AN/AOptionableTLGT, ONCS, ALRN, ADIL, and ADXS HeadlinesSourceHeadlineTopical pain reliever recalled for problem that can cause ‘severe morbidity, even death’charlotteobserver.com - June 7 at 10:18 AMβ1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzznews.google.com - May 13 at 1:32 AMLidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan Newsnews.google.com - May 13 at 1:32 AMGlobal Mobile Value-Added Services (VAS) Industry Market Report ... - Industry Todaynews.google.com - May 11 at 4:41 AMGlobal Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern Examinernews.google.com - May 8 at 10:54 AMDry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPRnews.google.com - May 8 at 5:54 AMMobile Value-Added Services (VAS) Market Size, Growth ... - Digital Journalnews.google.com - May 8 at 5:54 AMMobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern Examinernews.google.com - May 5 at 9:12 AMEpinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital Journalnews.google.com - May 3 at 7:08 AMErythromycin Market with Focus on Growth Analysis, Production ... - Digital Journalnews.google.com - May 2 at 8:42 AMFrom 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital Journalnews.google.com - April 29 at 8:17 AMTremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPRnews.google.com - April 28 at 10:17 PMDrugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPRnews.google.com - April 26 at 1:32 PMTopical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPRnews.google.com - April 26 at 8:32 AMTriamcinolone Market | Driving Factors, Industry Analysis ... - Taiwan Newsnews.google.com - April 24 at 4:23 PMIDT Corp. Cl Bwsj.com - April 23 at 2:59 AMMobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital Journalnews.google.com - April 17 at 2:17 PMHikma Names Injectables Chief Mishlawi As CEO - Generics Bulletinnews.google.com - April 12 at 1:13 PMMobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital Journalnews.google.com - April 10 at 1:16 PMEverstream Names Ken Fitzpatrick as President and Chief Executive ... - Joplin Globenews.google.com - April 6 at 1:58 PMLidocaine Ointment Market Growth Till, 2023-2030: Coherent Market ... - Digital Journalnews.google.com - March 29 at 7:08 AMMobile Value-Added Services (VAS) Maket Is Set to Fly High in ... - Digital Journalnews.google.com - March 29 at 2:07 AMGonorrhea Treatment Market Size 2023 - Current Sales Analysis, Upcoming Trends, Opportunities, Development His - openPRnews.google.com - March 28 at 10:26 AMBankruptcy Standing: An Introduction to a Multitude | Reed Smith ... - JD Supranews.google.com - March 25 at 8:59 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideeBay Steadily Climbs as Collectors Drive Growth March 25, 2024 6:29 AMView eBay Steadily Climbs as Collectors Drive Growth All Headlines Company DescriptionsAdial PharmaceuticalsNASDAQ:ADILAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Ayala PharmaceuticalsNASDAQ:ADXSAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Aileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.TeligentNASDAQ:TLGTTeligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.